The RoVI Study
What is the RoVI Study?
RoVI stands for Rotavirus Vaccine Immunogenicity: Impact of Maternal Antibodies & Microbiota
This study aims to understands why rotavirus vaccines protect babies from diarrhoea more efficiently in the UK and other high income countries than in poorer countries such as Malawi and India.
What are we doing?
In this study we want to understand what makes these vaccines work well in children in the UK, but worse in Malawi and India. Factors that impact on how well rotavirus vaccines protect children are likely to include:
- Maternal immunity passed to the baby in the womb or via breast milk.
- The baby’s gut bacteria (microbiota), which are also important for maintaining a healthy gut and helping with effective immune responses.
- Being exposed to other gut infections; Children living in poor countries are exposed to many infections, which lead to gut inflammation and may weaken the responses to the vaccines.
In this study we are measuring the protection transferred from the mothers to the babies during pregnancy and after birth. We will study the composition of the gut bacteria from birth to the time of rotavirus vaccination and study how this changes over the weeks in the baby and how it relates to the gut and breast milk bacteria of the mother’s. We will also investigate if particular gut bacteria are linked to better or worse responses to the rotavirus vaccine. The RoVI study is being conducted in three places, try to understand why rotavirus vaccines are less protective in the children in Malawi and India